Trial to Assess Chelation Therapy 2
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1000 participants.
Also called NCT02733185
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 1,000 participants
- Sponsor
- Registry
-
NCT02733185
-
- Other papers using this trial's data
- Edetate Disodium-Based Chelation for Patients With a Previous Myocardial Infarction and Diabetes: TACT2 Randomized Clinical Trial
- Multivitamins After Myocardial Infarction in Patients With Diabetes: A Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02733185. Randomized; triple masking; primary purpose prevention. Start 2016-10-01 (actual); primary completion 2023-06-30 (actual). Results posted on 2024-10-01.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Trial to Assess Chelation Therapy 2
- Acronym
- TACT2
- Condition
- Diabetes
- Condition
- Myocardial Infarction
- Intervention (Drug)
- disodium EDTA
- Intervention (Dietary supplement)
- Oral Multi Vitamins/Minerals (OMVM)
- Intervention (Drug)
- Placebo disodium EDTA
- Intervention (Dietary supplement)
- Placebo Oral Multi Vitamins/Minerals (OMVM)
- Lead sponsor
- Mt. Sinai Medical Center, Miami
- Collaborator
- National Center for Complementary and Integrative Health (NCCIH)
- Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator
- Duke Clinical Research Institute
Record details
- Record id
cardio:ct-nct02733185- Content hash
426f6bfc70b1d80ef1fe4b1894987c69cb3e5b73dbef3a99293579c309078724